Included Studies

Length of treatment

Daily Dosage

Age group of participants

(mean age)

Features fitting SCD and SCD plus criteria

[33]

(Beck et al., 2016)

short-term

(8 weeks)

240 mg/day standardized GBE

50 to 65 years

mean age 57 ± 4.6 years

Subjects with subjective memory impairment; slightly below average cognitive performance; fitting age group

[25]

(Vellas et al., 2012)

(GuidAge study)

[32]

(Scherrer, 2015)^a

long-term

(5 years)

240 mg/day standardized GBE

³ 70 years

mean age 76.4 ± 4.4 years

Subjects who spontaneously reported memory complaints, with or without concerns; fitting age group

[34] (Grass-Kapanke et al., 2011)

mid-term

(12 weeks)

240 mg/day standardized GBE

45 to 65 years

mean age 55.3±5.7 years

Subjects with subjective cognitive impairment incl. memory complaints; subjects with concerns; perceived impairment for at least 3 months; fitting age group

[35]

(Brautigam et al., 1998)

mid-term

(24 weeks)

120 drops/day standardized GBE (ginkgo biloba alcohol/water extract -Geriaforce) undiluted and diluted (1:1)

55 to 86 years

mean age 68.9 ± 7.8 years

Subjects who spontaneously reported memory and non-memory domain complaints; subjects with concerns; fitting age group

[36]

(Allain et al., 1993)

short-term

(3 weeks)

320 mg/day or 600 mg/day standardized GBE

60 to 80 years

mean age 69.3 ± 1.2 years

Subjects with mild to moderate memory impairment; fitting age group

[37]

(Rai et al., 1991)

mid-term

(24 weeks)

120 mg/day standardized GBE

> 50 years

mean age 73.42 ± 7.25 years

Subjects with mild to moderate memory impairment; impairment for at least 3 months; fitting age group

[38]

(Taillandier et al., 1986)

long-term

12 months

160 mg/day standardized GBE

> 60 years

mean age 82.35 ± 0.71 years

Subjects with age-associated memory and non-memory complaints, onset within the last 5 years, fitting age group